Ventyx Biosciences, Inc. (VTYX)

4.9200 +0.0100 (+0.20%) As of 03:41PM EDT. Market open.

Ventyx Biosciences, Inc.

12790 El Camino Real
Suite 200
San Diego, CA 92130
United States
760 593 4832
https://ventyxbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 79

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Sheila K. Gujrathi M.D.	Executive Chairperson	125k	N/A	1970
Dr. Raju S. Mohan Ph.D.	Founder, CEO, President & Director	905.29k	N/A	1958
Dr. John M. Nuss Ph.D.	Chief Scientific Officer	630.63k	N/A	1959
Dr. Martin Douglas Auster M.D.	Chief Financial Officer	N/A	N/A	1975

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

Corporate governance

Ventyx Biosciences, Inc.’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.